SHYNDEC(SH:600420) 智通财经网·2025-10-10 09:38Core Viewpoint - The announcement indicates that China National Pharmaceutical Group Modern (国药现代) has received approval for the active pharmaceutical ingredient (API) phosphoric acid sitagliptin, which is primarily used for improving blood sugar control in patients with type 2 diabetes [1] Group 1: Company Developments - The company's wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (国药威奇达), has received the "Approval Notice for Chemical Raw Material Drug Listing Application" from the National Medical Products Administration [1] - The approval signifies that the phosphoric acid sitagliptin API meets the regulatory requirements for drug registration in China, allowing it to be marketed domestically [1] - This development will further enrich the company's specialized API product portfolio [1]